Source-grounded facts extracted from VOLITIONRX LTD's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
VOLITIONRX LTD entered into Placement Agency Agreement with Maxim Group LLC (effective 2026-06-07).
“The Offering was conducted as a confidentially marketed public offering on a reasonable best efforts basis by Maxim acting as sole placement agent for the Company pursuant to a Placement Agency Agreement, dated June 7, 2026 (the “Placement Agency Agreement”).”
VOLITIONRX LTD entered into Purchase Agreement with the purchasers listed on the signature pages thereto valued at $1.55 per Share and accompanying Warrant (effective 2026-06-07).
“On June 7, 2026, VolitionRx Limited (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers listed on the signature pages thereto (the “Purchasers”), in connection with the Company’s offer of an aggregate of 2,960,000 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), together with accompanying common stock purchase warrants to purchase 1,480,000 shares of Common Stock (the “Warrants” and, together with the Shares, the “Securities”) to the Purchasers and other investors who purchased Securities pursuant to the prospectus registering such Securities (the “Offering”).”
Mickie Henshall departed as Director at VOLITIONRX LTD.
“On May 12, 2026, Mickie Henshall notified the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of her decision not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
VOLITIONRX LTD reported the first quarter 2026 results: revenue $1.0 million.
“pillars; our laser focus is on executing licensing agreements and we will update you as they progress.” 1 Financial Highlights · Revenue for the first quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025. · Operating loss was down 3% for the quarter versus the comparable quarter in 2025. · Net cash used in operating activities”
VOLITIONRX LTD: Amended the Certificate of Incorporation to effect a one-for-twenty reverse stock split and describe treatment of fractional shares (effective 2026-04-28).
“On April 27, 2026, the Company filed a Certificate of Third Amendment of the Second Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Delaware Secretary of State, which amended Section 6.1 of Article 6 of the Restated Certificate, effective as of 12:01 a.m. ET on April 28, 2026, to (i) give effect to the Reverse Stock Split, and (ii) describe the treatment of any fractional shares of Common Stock upon the effectiveness of the Reverse Stock Split.”
VOLITIONRX LTD reported full fiscal year 2025 results: revenue $1.7 million.
“Full-year revenue for 2025 was $1.7 million, representing growth of 40% over the previous year.”
VOLITIONRX LTD issued warrants to purchase up to an additional 483,870 shares of common stock of warrant to an existing stockholder for combined offering price of $0.62 per share and accompanying warrant, or an aggregate offering price of $300,000.
“on September 18, 2025 the Company issued 483,870 shares of its common stock, plus warrants to purchase up to an additional 483,870 shares of common stock at an exercise price of $0.682 per share, to an existing stockholder in a private placement, at a combined offering price of $0.62 per share and accompanying warrant, or an aggregate offering price of $300,000”
VOLITIONRX LTD issued 483,870 shares of its common stock of common stock to an existing stockholder for combined offering price of $0.62 per share and accompanying warrant, or an aggregate offering price of $300,000.
“on September 18, 2025 the Company issued 483,870 shares of its common stock, plus warrants to purchase up to an additional 483,870 shares of common stock at an exercise price of $0.682 per share, to an existing stockholder in a private placement, at a combined offering price of $0.62 per share and accompanying warrant, or an aggregate offering price of $300,000”
VOLITIONRX LTD issued 1,893,936 shares of common stock of common stock to Lind Global Asset Management XII LLC for $416,666 payment obligation.
“on January 16, 2026, the Company issued to Lind an aggregate of 1,893,936 shares of common stock to satisfy a $416,666 payment obligation”
VOLITIONRX LTD issued 2,569,753 shares of common stock of common stock to Lind Global Asset Management XII LLC for $583,334 payment obligation.
“on January 29, 2026, the Company issued to Lind an aggregate of 2,569,753 shares of common stock to satisfy a $583,334 payment obligation”
VOLITIONRX LTD issued 1,956,178 shares of common stock of common stock to Lind Global Asset Management XII LLC for $416,666 payment obligation.
“on February 17, 2026, the Company issued to Lind an aggregate of 1,956,178 shares of common stock to satisfy a $416,666 payment obligation”
VOLITIONRX LTD received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).
“February 6, 2026, VolitionRx Limited (the “Company”) received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders’ equit”
VOLITIONRX LTD issued 7,000,350 shares of warrant to Lind Global Asset Management XII LLC for $0.5714 per share.
“a Common Stock Purchase Warrant for the purchase of 7,000,350 shares of our common stock at a price of $0.5714 per share”
VOLITIONRX LTD issued convertible note to Lind Global Asset Management XII LLC for principal amount of $2,400,000.
“we will receive $2,000,000 in funding from Lind in exchange for the issuance to Lind of a Senior Secured Convertible Promissory Note in the principal amount of $2,400,000”
VOLITIONRX LTD amended Amended SPA with Lind Global Asset Management XII LLC valued at $2,000,000 (effective 2026-01-07).
“On January 7, 2026, VolitionRx Limited (the “Company”) entered into an amended and restated securities purchase agreement (the “Amended SPA”) with Lind Global Asset Management XII LLC, a Delaware limited liability company (“Lind”). Under the Amended SPA, within ten business days of signing, and subject to the satisfaction of certain closing conditions, we will receive $2,000,000 in funding from Lind”
VOLITIONRX LTD: Increased authorized shares from 175 million to 325 million via amendment to certificate of incorporation (effective 2025-06-18).
“On June 18, 2025, VolitionRx Limited (the " Company ") held its annual meeting of stockholders (the " Annual Meeting "). At the Annual Meeting, the Company’s stockholders approved a Certificate of Second Amendment (the " Amendment ") of the Second Amended and Restated Certificate of Incorporation (the " Restated Certificate "), providing for an increase in authorized shares from one hundred seventy-five million (175,000,000) shares to three hundred twenty-five million (325,000,000) shares, consisting of three hundred twenty-five million (325,000,000) shares of common stock, par value $0.001 per share. The Amendment had previously been approved by the Board of Directors on April 2, 2025, subject to the approval of the Company’s Stockholders. The Amendment became effective upon its filing with the Secretary of State of the State of Delaware on June 18, 2025.”
Dr. Ethel Rubin was appointed as Director at VOLITIONRX LTD.
“On September 30, 2024, the Board of Directors (the “ Board ”) of VolitionRx Limited (the “ Company ”), pursuant to the Company’s Bylaws, passed a resolution to increase the size of the Board to seven (7) members and appointed Dr. Ethel Rubin to fill the new vacancy on the Board effective as of September 30, 2024.”
VOLITIONRX LTD reported the first quarter of 2024 results: revenue approximately $170,000 in revenue.
“recorded approximately $170,000 in revenue in the first quarter of 2024, up 15% over the prior year”
VOLITIONRX LTD: Amended Bylaws to reduce stockholder meeting quorum from majority to 33 1/3% of voting power (effective 2024-04-24).
“On April 24, 2024, the Board adopted resolutions to amend the Company’s Bylaws to provide that the holders of 33 1/3% of the voting power of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, will constitute a quorum at all meetings of the stockholders for the transaction of business”
Guy Innes was appointed as Chairman of the Board at VOLITIONRX LTD.
“Assuming the re-election of the Board-nominated director nominees at the Annual Meeting, the Board has appointed Guy Innes as interim Chairman of the Board and as the Chair of the Nominations and Governance Committee, effective immediately upon such re-election, in addition to his continuing role as a member and Chair of the Audit Committee.”
Edward Futcher departed as Director at VOLITIONRX LTD.
“Dr. Faulkes will also step down as Executive Chairman, and Dr. Futcher will also step down as a member and Chair of the Board’s Nominations and Governance Committee and member of the Audit Committee, at the same time.”
Martin Faulkes departed as Executive Chairman at VOLITIONRX LTD.
“On April 24, 2024, Dr. Martin Faulkes and Dr. Edward Futcher each informed the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of their intention to retire from the Board of the Company following the conclusion of the current director service year and to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), which is expected to be held on July 2, 2024.”
VOLITIONRX LTD reported the full fiscal year ended December 31, 2023 results: revenue approximately $775,000.
“· Cash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9 million as of December 31, 2022. · Recorded approximately $775,000 in revenue in 2023, up 153% over the prior year. · Received $13.0 million in milestone payments from Heska Corporation in December 2023. · Net cash used in operating activities”
VOLITIONRX LTD reported the third quarter ended September 30, 2023 results: revenue $531,000.
“over the prior year period, reflecting sales of the reference kits through our global, regional and local supply agreements. Additionally, total year-to-date revenue was $531,000, a 185% increase compared to the comparable period of 2022. We believe that these results demonstrate steady growth, but not yet the “ramp” in revenues that we anticipate. We”
VOLITIONRX LTD reported financial results for second quarter ended June 30, 2023.
“VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the second quarter ended June 30, 2023.”
VOLITIONRX LTD shareholders approved Amendment to the 2018 Equity Incentive Plan (inferred from context) at the 2023-06-28 meeting.
“Proposal 4 : The Company’s stockholders approved the amendment to the Plan. The voting results are as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,541,886 13,692,776 352,056 11,936,520”
VOLITIONRX LTD shareholders approved Non-binding advisory vote on the compensation of the Company's named executive officers at the 2023-06-28 meeting.
“Proposal 3 : The stockholders approved, by a non-binding advisory vote, the compensation of the Company’s named executive officers as described in the Proxy Statement. The voting results are as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,678,808 13,455,552 452,358 11,936,520”
VOLITIONRX LTD shareholders approved Ratification of the selection of Sadler, Gibb & Associates, LLC as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-28 meeting.
“Proposal 2 : The stockholders ratified the selection of Sadler, Gibb & Associates, LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The voting results are as follows: Votes For Votes Against Votes Abstained 41,847,066 631,190 44,982”
VOLITIONRX LTD shareholders approved Election of eight members to the Board of Directors to hold office until the 2024 annual meeting at the 2023-06-28 meeting.
“Proposal 1 : The stockholders elected eight members to the Board of Directors to hold office until the 2024 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation or removal. The voting results are as follows: Nominee Votes For Votes Withheld Broker Non-Votes Dr. Phillip Barnes 17,190,976 13,395,742 11,936,520 Dr. Alan Colman 16,686,555 13,900,163 11,936,520 Dr. Martin Faulkes 17,893,663 12,693,055 11,936,520 Dr. Edward Futcher 16,702,277 13,884,441 11,936,520 Mickie Henshall 17,613,328 12,973,390 11,936,520 Guy Innes 16,601,593 13,985,125 11,936,520 Kim Nguyen 17,435,938 13,150,780 11,936,520 Cameron Reynolds 17,854,848 12,731,870 11,936,520”
VOLITIONRX LTD entered into Underwriting Agreement with Prime Executions, Inc., doing business as Freedom Capital Markets valued at approximately $15.4 million (effective 2023-06-01).
“On June 1, 2023, VolitionRx Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Prime Executions, Inc., doing business as Freedom Capital Markets (“Freedom”), as representative of the underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 13,000,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), to the Underwriters.”
VOLITIONRX LTD reported financial results for the first quarter ended March 31, 2023.
“VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the first quarter ended March 31, 2023.”
VOLITIONRX LTD reported the full fiscal year ended December 31, 2022 results: revenue approximately $300,000.
“$8.0 million in net cash (before deducting offering expenses payable by Volition) through an underwritten public offering of its common stock. · Recorded approximately $300,000 in revenue in 2022, up 240% over the prior year. · Received a $10 million upfront payment on signing the Heska Licensing and Supply Agreement. · During 2022, strengthened its”
VOLITIONRX LTD entered into Underwriting Agreement with Newbridge Securities Corporation (effective 2023-02-17).
“On February 17, 2023, VolitionRx Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”) pursuant to which the Company agreed to issue and sell an aggregate of 4,300,000 shares”
Dr. Jason Terrell resigned as Chief Medical Officer at VOLITIONRX LTD.
“On November 22, 2022, Dr. Jason Terrell tendered written notice to VolitionRx Limited (the “Company”) of his resignation as Chief Medical Officer of the Company, effective as of November 18, 2022.”
VOLITIONRX LTD reported financial results for third quarter ended September 30, 2022.
“On November 14, 2022, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2022.”
Mickie Henshall was appointed as Director at VOLITIONRX LTD.
“On August 15, 2022, the Board of Directors (the “ Board ”) of VolitionRx Limited (the “ Company ”), pursuant to the Company’s Bylaws, passed a resolution to increase the size of the Board to nine (9) members and appointed Ms. Mickie Henshall to fill the new vacancy on the Board effective as of August 15, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.